Clinical Trial News and Research

RSS

CWRU receives NCI grant to advance treatment of gastrointestinal cancers

The National Cancer Institute has awarded $11.3 million to Case Western Reserve University School of Medicine to establish a center of excellence for research on gastrointestinal cancers.

19 Sep 2011

New report finds decline in clinical trial recruitment for autoimmune disorders

The number of patients recruited to clinical trials for autoimmune disorders has waned in the last ten years, according to a new report available on companiesandmarkets.com.

19 Sep 2011

Case Western Reserve awarded $11.3M to establish gastrointestinal cancer research center

The National Cancer Institute has awarded $11.3 million to Case Western Reserve University School of Medicine to establish a center of excellence for research on gastrointestinal cancers. The funding designates the university as a Specialized Program of Research Excellence (SPORE) in Gastrointestinal (GI) Cancers - recognition extended to just one institution this year.

17 Sep 2011

Follow-up study of HIV vaccine trial provides clues for continued research

"After two years of analyzing the results of the largest AIDS vaccine clinical trial ever held -- called RV144 -- researchers say they have found two ways the immune system can respond, which could predict whether those inoculated will be protected or are more likely to become infected with HIV," CNN's health blog "The Chart" reports.

16 Sep 2011

Viewing video affects preferences for treatment of low back pain

Viewing an evidence-based video provides support to patients with low back pain in making decisions about whether to undergo surgical versus non surgical treatment, reports a study in a recent issue of Spine.

16 Sep 2011

Azithromycin gel may treat borreliosis in humans

Blood-sucking ticks are not just a nuisance, they can also transmit dangerous diseases. One of them is Lyme disease, which is caused by bacteria of the genus Borrelia, and requires a course of treatment with antibiotics lasting several weeks. LMU researchers have come up with a quicker alternative.

16 Sep 2011

Researchers identify promising new therapies for ependymoma

Researchers have identified promising new therapies for ependymoma, a rare tumor with few treatment options. St. Jude Children's Research Hospital investigators led the effort, which used a new, faster drug development system that combines the latest drug screening technology with the first accurate animal model of the tumor.

16 Sep 2011

Anavex Life Sciences to present data on lead compound for Alzheimer’s at Japan Neuroscience Society

Anavex Life Sciences Corp. will present the most recent data showing the therapeutic potential of ANAVEX compounds in animal models of Alzheimer’s disease at a special symposium of the 34th annual meeting of the Japan Neuroscience Society. The symposium is being held in Yokohama, Japan from September 15-17, 2011.

15 Sep 2011

International patient groups anxiously await start of Huntington’s trial

Prana Biotechnology Limited received a very positive reaction from international patient groups and researchers at this week’s World Congress on Huntington’s Disease in Melbourne. The company had a major presence at the Congress and the Prana team has held numerous meetings and conversations with patient groups and researchers.

15 Sep 2011

Loyola tests new pressure-sensing catheter to treat atrial fibrillation

Loyola University Medical Center is testing a high-tech catheter device that's intended to improve outcomes of patients treated for atrial fibrillation, the most common irregular heartbeat.

15 Sep 2011

Radiant to launch new division with dermal safety study

As part of their ongoing growth strategy, Radiant has been expanding its capabilities into the Consumer Products Testing arena. In order to supplement the existing Radiant staff that has years of consumer products testing experience, Radiant has hired key technical experts to serve as Study Managers, and to assist in training and certification of personnel.

15 Sep 2011

Cempra's solithromycin demonstrates efficacy comparable to levofloxacin for CABP treatment

Cempra Pharmaceuticals today announced results from its Phase II clinical trial investigating the efficacy, safety and tolerability of oral administration of our fourth generation macrolide, solithromycin (CEM-101), a fluoroketolide antibiotic, in comparison with oral levofloxacin for the treatment of community-acquired bacterial pneumonia (CABP).

15 Sep 2011

Patients with hepatitis C may benefit from 24 week telaprevir-based regimen

University of Cincinnati research published in the Sept. 14, 2011, advance online edition of the New England Journal of Medicine shows that patients with hepatitis C who took a combination medication-a telaprevir-based regimen that is commonly used to treat the illness-for 24 weeks were cured.

15 Sep 2011

Scientist granted over $138,000 to explore Vitamin C therapy in sepsis

Sepsis kills more people than breast, colorectal, pancreatic, and prostate cancers combined. Outside of coronary care units, it is the leading cause of mortality in intensive care units. Every year 18 million people worldwide develop this potentially fatal disease. Thanks to a generous grant of $138,238.65 from the Jesse and Julie Rasch Foundation, Lawson Health Research Institute's Dr. Michael Sharpe is exploring a new sepsis therapy using Vitamin C.

15 Sep 2011

Enrollment commences in ConjuChem's CJC-1134-PC Phase 2 trial for Type 2 diabetes

ConjuChem, LLC, a biotechnology company dedicated to the discovery of novel therapeutics, today announced it has initiated patient enrollment for its Phase 2 clinical trial of its proprietary GLP-1 receptor agonist drug, CJC-1134-PC, in patients with Type 2 diabetes mellitus who are receiving metformin monotherapy.

15 Sep 2011

Lucentis receives Health Canada approval to treat vision loss from DME

Health Canada has approved Lucentis (ranibizumab) as a treatment for vision loss resulting from diabetic macular edema, one of the major causes of adult vision loss and an important complication of the growing epidemic of diabetes.

14 Sep 2011

Miracor closes first round of Series B financing

Miracor Medical Systems GmbH, a private Austrian medical device company, announced today that the company has secured €7M/$10M in the first closing of the Series B financing round.

14 Sep 2011

Nanobiotix starts clinical trial of new cancer treatment for soft tissue sarcoma

Nanobiotix, a company developing novel cancer nanotherapeutics, announced today that its lead compound NBTXR3 has received the formal authorization from the French Medicine Agency, AFSSAPS, to start the first clinical trial.

14 Sep 2011

Tengion reinitiates enrollment in Neo-Urinary Conduit clinical trial for bladder cancer

Tengion, Inc. today announced that it has reinitiated enrollment of patients in the ongoing initial clinical trial of its lead product candidate, the Neo-Urinary Conduit, which is being evaluated in bladder cancer patients requiring a urinary diversion following bladder removal.

14 Sep 2011

ViroPharma initiates Cinryze Phase 2 subcutaneous trial in patients with HAE

ViroPharma Incorporated and Halozyme Therapeutics announced today that ViroPharma has initiated an open-label, multi-dose Phase 2 study to evaluate the safety, and pharmacokinetics and pharmacodynamics of subcutaneous administration of Cinryze in combination with Halozyme's Enhanze technology, a proprietary drug delivery platform using Halozyme's recombinant human hyaluronidase enzyme, in subjects with hereditary angioedema.

14 Sep 2011